Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults

Despite the increased numbers of older adults with inflammatory bowel diseases (IBDs), there are few studies regarding the safety and effectiveness of IBD treatments in older adults. The aim of this study was to compare the safety and effectiveness of anti –tumor necrosis factor (TNF)-α agents and vedolizumab in older adults with IBD.

Source: Clinical Gastroenterology and Hepatology - September 2, 2021 Category: Gastroenterology Authors: Bharati Kochar, Virginia Pate, Michael D. Kappelman, Millie D. Long, Ashwin N. Ananthakrishnan, Andrew T. Chan, Robert S. Sandler Source Type: research